What the Most Successful Drug Launches Reveal About Modern Pharma IP, Pricing, and Market Strategy
Recent successful drug launches indicate a trend toward more specialized, high-priced drugs that treat less-common medical conditions.
US Drug Spending: Where $603 Billion Goes, How IP Architecture Shapes Every Dollar, and What It Means for Pharma Investors
Prescription drugs are expensive to develop, and many intermediaries stand between patients and drug makers. Here’s where the money goes.
Orphan Drug Reform: How Mark Cuban’s Cost-Plus Model Is Forcing a Reckoning
1. Why This Matters Now Rare disease drugs now account for 52% of all new molecular entities (NMEs) approved by
Orphan Drug Reform: How Mark Cuban’s Cost-Plus Model Is Forcing a Reckoning Read Post »
AI Drug Discovery’s $110B Productivity Bet: What the Clinical Data Actually Shows
The cost of bringing a drug to market has crossed $2 billion. The Phase 2 failure rate sits near 60%.
AI Drug Discovery’s $110B Productivity Bet: What the Clinical Data Actually Shows Read Post »
Drug Patent Searching: The Definitive Intelligence Guide for Pharma Teams
For IP counsel, portfolio managers, R&D leads, and institutional investors who need to move faster than the competition. Why Drug
Drug Patent Searching: The Definitive Intelligence Guide for Pharma Teams Read Post »
Drug Repositioning: The Definitive Guide to Rescuing Shelved Assets for Rare, Orphan, and Neglected Diseases
1. The R&D Productivity Crisis: What the Numbers Actually Say The pharmaceutical industry’s core operating model has a compounding cost
PBMs, Formularies, and Rebates: What Investors Should Know
Deconstructing the Middleman: Beyond the Textbook Definition To truly grasp the PBM’s role, we must look past the simple definition
PBMs, Formularies, and Rebates: What Investors Should Know Read Post »
Drug Patent Expiry and Drug Price Erosion: The Definitive Analyst’s Guide to Loss of Exclusivity, Generic Entry, and Biosimilar Market Dynamics
1. The Scale of the Cliff: $236 Billion in Revenue at Risk Through 2030 The pharmaceutical industry is heading into
The Generic Drug Maker’s Escape Route: How 505(b)(2) Turns Commodities into Cash Cows
Generic drug companies fill more than 90% of all U.S. prescriptions and have saved the healthcare system an estimated $3.1
The Generic Drug Maker’s Escape Route: How 505(b)(2) Turns Commodities into Cash Cows Read Post »
